Dependence of the anti-CD66 antibody biodistribution on the dissociation constant: A simulation study

Zeitschrift fur Medizinische Physik

Volumn 21, Issue 4, 2011, Pages 301-304

  Kletting, Peter ^a   Reske, Sven N ^a   Glatting, Gerhard ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

Anti CD66 antibody; Dissociation constant; Model simulations; Radioimmunotherapy; Therapeutic index

Indexed keywords

ANTIBODY; CD66 ANTIBODY; UNCLASSIFIED DRUG;

ANALYTICAL PARAMETERS; ANTIGEN ANTIBODY COMPLEX; ANTIGEN EXPRESSION; ARTICLE; COMPUTER SIMULATION; DISSOCIATION CONSTANT; DRUG DISTRIBUTION; MATHEMATICAL MODEL; PREDICTION; QUANTITATIVE ANALYSIS; RADIOIMMUNOTHERAPY; THERAPEUTIC INDEX;

ALGORITHMS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; BONE MARROW; CELL ADHESION MOLECULES; COMPUTER SIMULATION; HUMANS; IMMUNOLOGIC TECHNIQUES; MODELS, THEORETICAL; RADIOIMMUNOTHERAPY; TISSUE DISTRIBUTION; YTTRIUM RADIOISOTOPES;

EID: 83255186692     PISSN: 09393889     EISSN: 18764436     Source Type: Journal    
DOI: 10.1016/j.zemedi.2011.03.003     Document Type: Article

References (13)

1. 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study. Br J Haematol. 2005, 130:604-613.
2. Orchard K.H., Cooper M., Lewington V., Tristam M., Zivanovic M., Thom J. Targeted radiotherapy in haematopoietic stem cell transplantation: results of a phase I trial using an Yttrium-90-labelled anti-CD66 murine monoclonal antibody demonstrating consistent BM targeting. Bone Marrow Transplantation. 2006, 37:S45-S46.
3. Bunjes D., Buchmann I., Duncker C., Seitz U., Kotzerke J., Wiesneth M. Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study. Blood. 2001, 98:565-572.
4. Kletting P., Kull T., Bunjes D., Mahren B., Luster M., Reske S.N. Radioimmunotherapy with anti-CD66 antibody: Improving the biodistribution using a physiologically based pharmacokinetic model. J Nucl Med. 2010, 51:484-491.
5. Thomas G.D., Chappell M.J., Dykes P.W., Ramsden D.B., Godfrey K.R., Ellis J.R. Effect of dose, molecular size, affinity, and protein binding on tumor uptake of antibody or ligand: a biomathematical model. Cancer Res. 1989, 49:3290-3296.
6. Kletting P., Bunjes D., Reske S.N., Glatting G. Improving anti-CD45 antibody radioimmunotherapy using a physiologically based pharmacokinetic model. J Nucl Med. 2009, 50:296-302.
7. Nestorov I. Whole-body physiologically based pharmacokinetic models. Expert Opin Drug Metab Toxicol. 2007, 3:235-249.
8. Kaufman E.N., Jain R.K. Effect of Bivalent Interaction upon Apparent Antibody Affinity: Experimental Confirmation of Theory Using Fluorescence Photobleaching and Implications for Antibody Binding Assays. Cancer Res. 1992, 52:4157-4167.
9. Barrett P.H., Bell B.M., Cobelli C., Golde H., Schumitzky A., Vicini P. SAAM II: Simulation, Analysis, and Modeling Software for tracer and pharmacokinetic studies. Metabolism. 1998, 47:484-492.
10. Dower S.K., Segal D.M. Interaction of monoclonal antibodies with MHC class I antigens on mouse spleen cells. II. Levels of expression of H-2K, H-2D, and H-2L in different mouse strains. J Immunol. 1985, 134:431-435.
11. Ong G.L., Mattes M.J. Re-evaluation of the concept of functional affinity as applied to bivalent antibody binding to cell surface antigens. Mol Immunol. 1993, 30:1455-1462.
12. Steinsträßer A., Berberich R., Kuhlmann L., Zabori S., Schwarz A. Bindung des monoklonalen Antikörpers BW 250/183 an menschliche Granulozyten [Binding of Monoclonal Antibody BW 250/183 to Human Granulocytes]. Nuklearmedizin. 1992, 31:57-63.
13. Nieri P., Donadio E., Rossi S., Adinolfi B., Podesta A. Antibodies for therapeutic uses and the evolution of biotechniques. Curr Med Chem. 2009, 16:753-779.